Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Northwestern University Human Resources

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1851-01-28

Employees: 5K

Market Cap: -

Website: https://www.venturecat.northwestern.edu

Clinical Trials

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: Carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-01

Lead Sponsor: Northwestern University

Target Recruit Count: 44

Registration Number: NCT00058292

Locations: 🇺🇸
Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Liver Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Target Recruit Count: 8

Registration Number: NCT00057980

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer
Lung Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Registration Number: NCT00058006

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 1 locations

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Registration Number: NCT00057993

Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-04-09

Last Posted Date: 2019-02-06

Lead Sponsor: Northwestern University

Target Recruit Count: 37

Registration Number: NCT00057967

Locations: 🇺🇸
Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004231

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Recruiting

Conditions: Endometrial Cancer
Sarcoma
Vulvar Cancer
Cervical Cancer
Fallopian Tube Cancer
Ovarian Cancer
Uterine Leiomyomata
Hereditary Breast/Ovarian Cancer (brca1, brca2)
Vaginal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2025-02-28

Lead Sponsor: Northwestern University

Target Recruit Count: 6000

Registration Number: NCT00005095

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004896

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

PS-341 in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-07-29

Lead Sponsor: Northwestern University

Registration Number: NCT00028639

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer

Completed

Conditions: Breast Cancer
Osteoporosis

First Posted Date: 2003-01-27

Last Posted Date: 2011-02-21

Lead Sponsor: Northwestern University

Target Recruit Count: 79

Registration Number: NCT00005605

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy